Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, Matthew A Booker, Nicole A Traphagen, Kenny Weng, Nathaniel C Voss, Navin R Mahadevan, Kei Mizuno, Loredana Puca, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Research square. 2024
Gian Marco Franceschini, Orsetta Quaini, Kei Mizuno, Francesco Orlando, Yari Ciani, Sheng-Yu Ku, Michael Sigouros, Emily Rothmann, Alicia Alonso, Matteo Benelli, et al. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation. Cancer discovery. 2024. 14. 3. 424-445
Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Shengyu Ku, Ladan Fazli, et al. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. Journal of the National Cancer Institute. 2024. 116. 1. 115-126
Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, Ze-Hua Li, Koji Haratani, Caroline G Fahey, Keiichi Ota, Navin R Mahadevan, Yingxiao Shi, Shin Saito, et al. TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity. Cancer discovery. 2024
Takashi Matsuoka, Aiko Sugiyama, Yoshifumi Miyawaki, Yusuke Hidaka, Yukiko Okuno, Hiroaki Sakai, Hiroki Tanaka, Kiyotsugu Yoshikawa, Tomohiro Fukui, Kei Mizuno, et al. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide. Cancer science. 2024. 115. 1. 283-297
